These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1384935)

  • 21. Effect of 3,4-methylenedioxymethamphetamine on [3H]paroxetine binding in the frontal cortex and blood platelets of rats.
    Nash JF; Arora RC; Schreiber MA; Meltzer HY
    Biochem Pharmacol; 1991 Jan; 41(1):79-84. PubMed ID: 1702633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue.
    Johnson MP; Huang XM; Nichols DE
    Pharmacol Biochem Behav; 1991 Dec; 40(4):915-22. PubMed ID: 1726189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.
    Schmidt CJ
    J Pharmacol Exp Ther; 1987 Jan; 240(1):1-7. PubMed ID: 2433425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chloral hydrate anesthesia antagonizes the neurotoxicity of 3,4-methylenedioxymethamphetamine.
    Schmidt CJ; Black CK; Abbate GM; Taylor VL
    Eur J Pharmacol; 1990 Nov; 191(2):213-6. PubMed ID: 1982264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans.
    McCann UD; Ridenour A; Shaham Y; Ricaurte GA
    Neuropsychopharmacology; 1994 Apr; 10(2):129-38. PubMed ID: 7517677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans.
    Steele TD; McCann UD; Ricaurte GA
    Addiction; 1994 May; 89(5):539-51. PubMed ID: 7913850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA).
    Paris JM; Cunningham KA
    Brain Res Bull; 1992 Jan; 28(1):115-9. PubMed ID: 1347247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurochemical basis of neurotoxicity.
    Gibb JW; Johnson M; Hanson GR
    Neurotoxicology; 1990; 11(2):317-21. PubMed ID: 1978271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of 3,4-methylenedioxymethamphetamine metabolism leads to marked decrease in 3,4-dihydroxymethamphetamine formation but no change in serotonin neurotoxicity: implications for mechanisms of neurotoxicity.
    Mueller M; Yuan J; Maldonado Adrian C; McCann UD; Ricaurte GA
    Synapse; 2011 Oct; 65(10):983-90. PubMed ID: 21360595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity.
    Johnson M; Stone DM; Bush LG; Hanson GR; Gibb JW
    Eur J Pharmacol; 1989 Feb; 161(2-3):181-8. PubMed ID: 2470597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase.
    Bai F; Jones DC; Lau SS; Monks TJ
    Chem Res Toxicol; 2001 Jul; 14(7):863-70. PubMed ID: 11453733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of neurotoxicity after intra-raphe micro-injections of MDMA ("ecstasy").
    Paris JM; Cunningham KA
    NIDA Res Monogr; 1990; 105():333-4. PubMed ID: 1715034
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug effects on distribution of [3H]3,4-methylenedioxymethamphetamine in mice.
    Hashimoto K; Maeda H; Hirai K; Goromaru T
    Eur J Pharmacol; 1993 Apr; 228(5-6):247-56. PubMed ID: 8097718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence.
    McCann UD; Ricaurte GA
    J Clin Psychopharmacol; 1993 Jun; 13(3):214-7. PubMed ID: 8102623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine.
    Schmidt CJ; Black CK; Taylor VL
    Eur J Pharmacol; 1990 May; 181(1-2):59-70. PubMed ID: 1974858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats.
    Stone DM; Hanson GR; Gibb JW
    Neuropharmacology; 1987 Nov; 26(11):1657-61. PubMed ID: 2448703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurotoxic effect of MDMA on brain serotonin neurons: evidence from neurochemical and radioligand binding studies.
    De Souza EB; Battaglia G; Insel TR
    Ann N Y Acad Sci; 1990; 600():682-97; discussion 697-8. PubMed ID: 1979218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striatal neurotensin and dynorphin A concentrations.
    Johnson M; Bush LG; Hanson GR; Gibb JW
    Biochem Pharmacol; 1993 Aug; 46(4):770-2. PubMed ID: 8103327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain.
    Gibb JW; Stone DM; Stahl DC; Hanson GR
    NIDA Res Monogr; 1987; 76():316-21. PubMed ID: 2449619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats.
    Schmidt CJ; Abbate GM; Black CK; Taylor VL
    J Pharmacol Exp Ther; 1990 Nov; 255(2):478-83. PubMed ID: 1978728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.